Skip to main content

ASCIA Submissions 2024

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

  • ASCIA letter of support for application on the agenda of the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting: Arexvy® Respiratory Syncytial Virus (RSV) Vaccine application for new NIP listing - Lodged 29 May 2024.
    pdfASCIA letter PBAC AREXVY 2024-05-2952.02 KB